TABLE 2.

Use of immunosuppressive therapies, thromboprophylaxis, and blood products in 146 dogs with immune‐mediated hematological disorders

	mTPE group	Controls	P
Immunosuppressive treatment	n = 17	n = 129
Prednisolone/dexamethasone	17 (100%)	128 (99%)	n/a
Cyclosporine	10 (59%)	77 (60%)	.95
Mycophenolate mofetil	8 (47%)	29 (23%)	.03*
IVIG	2 (12%)	27 (21%)	.53
Leflunomide	0 (0%)	1 (1%)	n/a
Vincristine	2 (12%)	19 (15%)	1.00
Average number of ISD during hospitalization	1.9 (1.8‐2.1)	1.7 (1.0‐2.0)	.009*
Peak number of ISD	3.0 (3.0‐3.0)	2.0 (2.0‐2.0)	<.001*
Number of ISD at discharge or death	2.0 (2.0‐2.0)	2.0 (1.0‐2.0)	.06
Thromboprophylaxis
Aspirin	1 (6%)	35 (27%)	.07
Clopidogrel	10 (59%)	41 (32%)	.03*
Low‐molecular weight heparin	1 (6%)	2 (2%)	n/a
Rivaroxaban	1 (6%)	0 (0%)	n/a
Blood products
Packed red blood cells	12 dogs (71%), mean 1.65 U/dog	70 dogs (54%), mean 0.83 U/dog	.2
Whole blood	2 dogs (12%), mean 0.18 U/dog	10 dogs (8%), mean 0.10 U/dog	.63
Oxyglobin	1 dog (6%), mean 0.06 U/dog	1 dog (6%), mean 0.01 U/dog	n/a
Fresh‐frozen plasma	17 dogs (100%), mean 4.29 U/dog	1 dog (1%), mean 0.02 U/dog	n/a

Notes: Numerical data are presented as median (IQR) and proportions as numbers (%). Following immunosuppressive drug (ISD) and antithrombotics doses were used: prednisolone, 2 mg/kg q12‐24h PO; dexamethasone, 0.3 mg/kg q24h IV; cyclosporine, 3‐5 mg/kg q12‐24h PO; mycophenolate mofetil, 8‐10 mg/kg q12h PO; IVIG, 0.3‐1 g/kg IV (single dose); leflunomide, 4 mg/kg q24h PO; vincristine, 0.02 mg/kg IV (single dose); aspirin, 2‐5 mg/kg q24h PO; clopidogrel, 1‐2 mg/kg q24h PO; low‐molecular weight heparin (dalteparin), 150 IU/kg q8h SC; rivaroxaban, 1 mg/kg q24h PO.

*Indicates a statistically significant difference